GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri®Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3...
Covered in this story
Call it yourself
No calls on $GRAL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Grail Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.